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Background
Standard chemoradiation with cisplatin has improved the
results of treatment, however, newer therapeutical modal-
ities are needed. DNA demethylating and histone deacety-
lase inhibitors have shown radiosensitizing effects as well
as potentiation of chemotherapy drugs. This study was set
to evaluate hydralazine and valproate as epigenetic ther-
apy added to chemoradiation with cisplatin in cervical
cancer.
Materials and methods
Eligibility criteria included untreated disease, histological
diagnosis and adequate bone marrow, hepatic and liver
function. Patients were typed for acetylator phenotype
and then oral hydralazine at 182 mg/day or 83 mg/day for
rapid and slow-acetylators respectively. Oral magnesium
valproate was used at 30 mg/Kg/day. Treatment started 7
days before commencing chemoradiation. Chemoradia-
tion consisted on EBRT 50 Gy in 2G fractions plus cispla-
tin at 40 mg/m2 weekly × 6. Brachytherapy was scheduled
after EBRT. Response, toxicity and survival were evaluated
as well as the biological effects of hydralazine and val-
proate in blood and primary tumor samples.
Results
Twenty one patients were included. Mean age was 50.4
years (range: 28–69 y). Overall, 85% of patients com-
pleted both phases, external beam and intracavitary ther-
apy. Three patients did not receive brachytherapy: two
abandoned treatment during EBRT and one died after the
first cycle of chemotherapy. Mean + SD dose administered
to point A was 84.6 + 2.2 (range: 79.6 – 87 for point A).
Median number of cisplatin cycles administered was five
(range 1–6). The 18 patientes evaluable for response
achieved complete clinical response after EBRT. The most
frequent grade 3/4 hematological toxicity was neutrope-
nia (45%), followed by thrombocytopenia (10%) and
anemia (10%). Non-hematological toxicity was mild in
most of cases. Three out of 18 cases have relapsed
(16.6%): one local, one had local/systemic relapse and
one systemic, at a median follow-up of 11 months (range:
1 – 13.4 m). The hydralazine/valproate-induced changes
in the expression of genes analyzed by microarrays will be
presented in the meeting.
Conclusion
Epigenetic therapy with hydralazine and valproate associ-
ated to chemoradiation in cervical cancer is well-tolerated
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and seems effective as all evaluable patients achieved clin-
ical complete response during the external radiation.